PRODUCT INFORMATION

M2698

Item No. 36816

CAS Registry No.:	1379545-95-5
Formal Name:	4-[[(1S)-2-(1-azetidinyl)-1-[4-chloro-3-(trifluoromethyl)phenyl]ethyl]amino]-8-quinazolinecarboxamide
Synonym:	MSC2363318A
MF:	$C_{21}H_{19}ClF_3N_5O$
FW:	449.9
Purity:	≥98%
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

M2698 is supplied as a solid. A stock solution may be made by dissolving the M2698 in the solvent of choice, which should be purged with an inert gas. M2698 is soluble in DMSO.

Description

M2698 is a dual inhibitor of p70 ribosomal S6 kinase (p70S6K) and Akt1 (IC_{50}s = 1.1 and 4 nM, respectively).[1] It is selective for p70S6K and Akt1 over Aurora B kinase (IC_{50} = 170 nM), as well as a panel of 265 kinases at 1 µM, but also inhibits protein kinase A (PKA), p90 ribosomal S6 kinase 1 (MSK1), MSK2, cGMP-dependent protein kinase 1α (PKG1α), PKG1β, and protein kinase X (PRKX). M2698 reduces tumor volume in MiaPaCa-2 pancreatic cancer and A549 non-small cell lung cancer (NSCLC) mouse xenograft models when administered at doses of 20 or 30 mg/kg, respectively.

Reference

1. DeSelm, L., Huck, B., Lan, R., *et al.* Identification of clinical candidate M2698, a dual p70S6K and Akt inhibitor, for treatment of PAM pathway-altered cancers. *J. Med. Chem.* **64(19)**, 14603-14619 (2021).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM